149 unknown, 103 recruiting, 62 not yet recruiting, 31 completed. 372 Phase 2, 35 Phase 1, 16 Phase 3.
Follow sintilimab: new trials by email Literature Review of sintilimab trials Research Report on sintilimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal Mesothelioma Sintilimab, Ipilimumab N01, Bevacizumab - Peritoneal Mesothelioma, First-line Therapy | Phase 2 | Not yet recruiting | Fudan University | 19 | 2026-10-30 | 2026-10-23 |
| A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction Cancer Ipilimumab N01, Sintilimab - Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Fudan University | 36 | 2026-10-20 | 2026-10-16 |
| Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for High-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled Trial Ipilimumab & Sintilimab, Sintilimab - Locally Advanced Rectal Cancer (LARC) | Phase 2 / Phase 3 | Not yet recruiting | Yao Hongwei | 120 | 2026-10-01 | 2026-10-19 |
| Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for Low/Intermediate-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled Trial Ipilimumab & Sintilimab, Sintilimab - Locally Advanced Rectal Cancer (LARC) | Phase 2 / Phase 3 | Not yet recruiting | Yao Hongwei | 120 | 2026-10-01 | 2026-10-19 |
| Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma CT-guided percutaneous local ablation, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Neoplasm Metastasis | Phase 2 | Not yet recruiting | Sun Yat-sen University | 138 | 2026-10-01 | 2026-09-17 |
| A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric Cancer Fruquintinib, Sintilimab, Irinotecan Hydrochloride Liposome Injection (II) - Stomach Neoplasms, Gastric Cancer | Phase 2 | Not yet recruiting | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | 20 | 2026-10-01 | 2026-09-14 |
| Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma SYS6090 Injection + Bevacizumab Injection, SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection, Bevacizumab Injection + Sintilimab Injection - HCC - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 288 | 2026-09-30 | 2026-08-12 |
| Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer Tafolecimab, Sintilimab - Colon Cancer, PCSK9 Inhibitor | Phase 2 | Recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 70 | 2026-09-20 | 2026-09-25 |
| Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study Sintilimab, ipilimumab, Radscopal Radiotherapy - Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 28 | 2026-09-01 | 2026-08-10 |
| GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma Gemcitabine (GEM), Etoposide Injection, Dexamethasone - Natural Killer/T-cell Lymphoma | Phase 2 | Not yet recruiting | Fudan University | 620 | 2026-09-01 | 2026-08-17 |
| Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma Paclitaxel polymer micelles for injection and cisplatin combined with sintilimab - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 32 | 2026-09-01 | 2026-09-02 |
| SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer SBRT + Ipilimumab N01 + Sintilimab + AG Chemotherapy - Pancreatic Cancer | Phase 2 | Recruiting | Shandong Cancer Hospital and Institute | 47 | 2026-08-05 | 2026-10-13 |
| Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial Ipilimumab Injection, Sintilimab injection, Lenvatinib - Renal Cell Carcinoma (Kidney Cancer), Immunotherapy | Phase 2 | Not yet recruiting | West China Hospital | 66 | 2026-08-01 | 2026-07-20 |
| A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma Sintilimab, disitamab vedotin - Sebaceous Gland Carcinoma | Phase 2 | Not yet recruiting | West China Hospital | 25 | 2026-08-01 | 2026-08-03 |
| Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma tegafur, Gimeracil and Oteracil Potassium Capsules, Sintilimab Placebo, Sintilimab - Resectable Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 720 | 2026-07-31 | 2026-08-14 |
| Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial Cetuximab, Irinotecan, Bevacizumab - Colorectal Neoplasms Malignant, Neoplasm, Metastatic | Phase 2 | Recruiting | Guangdong Provincial People's Hospital | 160 | 2026-07-23 | 2026-09-24 |
| Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet) IBI310+ sintilimab + bevacizumab, IBI310+ sintilimab, sintilimab + bevacizumab - Resectable Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 90 | 2026-07-20 | 2026-07-20 |
| Sintilimab Plus Gossypol Acetate in Advanced Colorectal Cancer Sintilimab, Gossypol Acetate - Advanced Colorectal Cancer | Phase 2 | Not yet recruiting | Peking University People's Hospital | 32 | 2026-07-15 | 2026-06-25 |
| Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer Multimodal Thermal Therapy (MTT) System, KRAS G12V mRNA Vaccine, Sintilimab - Pancreatic Ductal Adenocarcinoma, Liver Neoplasms | Phase 2 | Not yet recruiting | Ruijin Hospital | 20 | 2026-07-13 | 2026-08-04 |
| Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer Sintilimab + GC, SBRT 7Gy✖️5 QD - Biliary Tract Cancer (BTC) | Phase 2 | Not yet recruiting | Eastern Hepatobiliary Surgery Hospital | 123 | 2026-06-15 | 2026-06-10 |
Showing 20 of 372. Sign in to see all of them.
Carcinoma, Hepatocellular (44) · Stomach Neoplasms (42) · Carcinoma, Non-Small-Cell Lung (24) · Colorectal Neoplasms (18) · Esophageal Squamous Cell Carcinoma (13) · Rectal Neoplasms (11) · Lung Neoplasms (10) · Nasopharyngeal Carcinoma (10) · Pancreatic Neoplasms (8) · Esophageal Neoplasms (7) · Neoplasm Metastasis (7) · Cholangiocarcinoma (6) · Colonic Neoplasms (6) · Neoplasms (6) · Squamous Cell Carcinoma of Head and Neck (6)
Fudan University (41) · Sun Yat-sen University (39) · Tianjin Medical University Cancer Institute and Hospital (21) · The First Affiliated Hospital with Nanjing Medical University (13) · Zhejiang Cancer Hospital (13) · West China Hospital (10) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (9) · Innovent Biologics (Suzhou) Co. Ltd. (9) · Second Affiliated Hospital, Zhejiang University, School of Medicine (8) · Ruijin Hospital (7) · Peking Union Medical College Hospital (6) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (6) · Henan Cancer Hospital (5) · Sichuan University (5) · Zhejiang University (5)
China (318) · United States (4) · Australia (1) · France (1) · Germany (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Peng Wang, MD (7) · Hao Zeng, Doctor (2) · Jing-wen Wang, M.D. (2) · Kangshun Zhu, Dr. (2) · Lin Wu (2) · Mian Xi, MD (2) · Yi-Long Wu (2) · Yunpeng Liu, PhD (2) · Zhen Zhang, M.D, PH.D (2) · Aiping Zhou, M.D. (1) · Baocai Xing, Doctor (1) · Biyun Wang, Prof (1)
PMID 34143971, PMID 34702811, PMID 15496622, PMID 18559976, PMID 19387333, PMID 20548096, PMID 20728210, PMID 21879261, PMID 22646630, PMID 24094768, PMID 24403232, PMID 25240821, PMID 25991832, PMID 26291008, PMID 26480849, PMID 26884585, PMID 27389519, PMID 28314688, PMID 28493288, PMID 28823862, PMID 29095678, PMID 29366520, PMID 29398921, PMID 29543938, PMID 29658856, PMID 29787422, PMID 29966520, PMID 29967015, PMID 30089078, PMID 30172698, PMID 30207593, PMID 30558224, PMID 30612710, PMID 30620669, PMID 30718072, PMID 30770362, PMID 30826965, PMID 30975638, PMID 31209394, PMID 31294749, PMID 31320661, PMID 31463890, PMID 32077550, PMID 32332722, PMID 32965635, PMID 33026938, PMID 33130217, PMID 33316218, PMID 33504550, PMID 33510460